文献速递消化内镜消化道出血消化道肿瘤与早癌

抗血栓治疗对胃内镜切除术后迟发性出血影响的比较:倾向性评分匹配病例对照研究

Comparison of the effects of antithrombotic therapy on delayed bleeding after gastric endoscopic resection: a propensity score-matched case-control study.
PubMed 文献 · Gastrointest Endosc · 2018-08-24

该研究纳入2011年1月至2017年3月因单发胃肿瘤行内镜切除的7752例患者共8242处病变,经2:1倾向性评分匹配后比较798处对照病变与399处抗血栓治疗病变。抗血栓组迟发性出血率10.0%高于对照组6.3%,继续用药者及肝素桥接治疗者出血风险更高,未观察到血栓栓塞事件。

要点

  • 抗血栓治疗组迟发性出血率10.0%,高于对照组的6.3%。
  • 继续使用抗血栓药物者迟发性出血率15.9%,高于匹配对照的5.1%(比值比3.55)。
  • 抗凝药患者中肝素桥接治疗者迟发性出血率35.7%,高于非桥接者的10.0%(比值比5.00)。

核心结论

  • 接受抗血栓治疗的患者迟发性出血发生率高于未接受抗血栓治疗者,尤其是继续使用抗血栓药物和接受肝素桥接治疗的患者。

研究设计与样本

  • 研究为倾向性评分匹配病例对照研究,纳入2011年1月至2017年3月因单发胃肿瘤行内镜切除的7752例患者共8242处病变;按年龄、性别、标本大小、肿瘤位置、诊断、慢性肾病和肝硬化进行2:1倾向性评分匹配,匹配后对照病变798处、抗血栓治疗病变399处。

主要发现

  • 对照病变与抗血栓治疗病变的迟发性出血率分别为6.3%和10.0%。
  • 两组早期迟发性出血率无显著差异,但抗血栓治疗组晚期迟发性出血率高于对照组。
  • 抗血栓治疗组中继续用药者迟发性出血发生率15.9%,高于其匹配对照的5.1%(比值比3.55;95%置信区间1.24-10.14;P=0.018)。
  • 服用抗凝药的患者中,肝素桥接治疗者迟发性出血发生率35.7%,高于非桥接者的10.0%(比值比5.00;95%置信区间1.11-22.50;P=0.036)。
  • 服用抗血栓药物的患者中未观察到血栓栓塞事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Antithrombotic (AT) therapy has been known to increase post-endoscopic resection (ER) bleeding risk; however, there are few studies quantifying the effect of AT agents. This study aimed to analyze the incidence of delayed bleeding (DB) based on AT agents administered and to identify the proper timing of drug cessation. METHODS: Between January 2011 and March 2017, 7752 patients with 8242 lesions underwent ER for single gastric neoplasm. After a 2:1 propensity score matching using age, sex, specimen size, tumor location, diagnosis, chronic kidney disease, and liver cirrhosis, 798 and 399 lesions were classified as belonging to the matched control (MC) group and AT group, respectively. The clinical outcomes were compared between the 2 groups. RESULTS: The DB rate of the MC and AT groups was 6.3% and 10.0%, respectively. There was no significant difference in the early DB rate between the 2 groups; however, the late DB rate of the AT group was higher than the MC group. The continuation group of the AT group had a higher incidence of DB than their matched control subjects (15.9% vs 5.1%; odds ratio, 3.55; 95% confidence interval, 1.24-10.14; P = .018). In patients taking anticoagulants, heparin bridging therapy (HBT) increased the incidence of DB compared with non-HBT (35.7% vs 10.0%; odds ratio, 5.00; 95% confidence interval, 1.11-22.50; P = .036). No thromboembolic events were observed in patients taking AT agents. CONCLUSIONS: Patients receiving AT therapy had a higher incidence of DB than those not receiving AT therapy, especially with the continued administration of AT agents and HBT.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. So S, Ahn JY, Kim N, et al. Comparison of the effects of antithrombotic therapy on delayed bleeding after gastric endoscopic resection: a propensity score-matched case-control study. Gastrointest Endosc. 2018. PMID: 30145315. doi:10.1016/j.gie.2018.08.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。